RECRUITING

A Study of YL242 in Subjects With Advanced Solid Tumors

Talk to us

Conditions

Advanced Solid TumorOncologyVEGFAntibody drug conjugateDevelopmental Phase I/II

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.

Official Title

A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors.

Quick Facts

Study Start:2025-09-22
Study Completion:2028-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07197827

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Aged ≥18 years.
  2. * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
  3. * Adequate organ and bone marrow function
  4. * Tumor type:
  1. * Be intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor
  2. * Uncontrolled or clinically significant cardiovascular and cerebrovascular diseases
  3. * Clinically significant concomitant pulmonary disease
  4. * A history of leptomeningeal carcinomatosis or carcinomatous meningitis
  5. * Any illness, medical condition, organ system dysfunction, or social situation, including but not limited to mental illness or substance/alcohol abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, adversely affect the patient's ability to cooperate and participate in the study, or compromise the interpretation of study results

Contacts and Locations

Study Contact

Medilink Study Team
CONTACT
+86 0512-62858368
clinicaltrials@medilinkthera.com

Study Locations (Sites)

US-201
New Haven, Connecticut, 06519
United States
US-202
Sarasota, Florida, 34232
United States
US-204
Boston, Massachusetts, 02215
United States
US-206
Grand Rapids, Michigan, 49546
United States
US-205
Nashville, Tennessee, 37203
United States
US-203
Houston, Texas, 77030
United States
US-207
San Antonio, Texas, 78229
United States

Collaborators and Investigators

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09-22
Study Completion Date2028-11

Study Record Updates

Study Start Date2025-09-22
Study Completion Date2028-11

Terms related to this study

Keywords Provided by Researchers

  • Oncology
  • VEGF
  • Antibody drug conjugate
  • Developmental Phase I/II

Additional Relevant MeSH Terms

  • Advanced Solid Tumor